Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Erik Vandendries(Pfizer (United States)), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Nicola Gökbuget(Goethe University Frankfurt), Giovanni Martinelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alexander Neuhof(Pfizer (Germany)), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Wendy Stock(University of Chicago), Michaela Liedtke(Cancer Prevention Institute of California), Kevin T. Nguyen(Diabetes Technology Society), Alexander Laird(Pfizer (United States)), Tao Wang(Chinese Academy of Sciences), Susan O’Brien(The University of Texas MD Anderson Cancer Center), Anjali S. Advani(Cleveland Clinic), Matthias Stelljes(University Hospital Münster)
Cited by 52
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k